Schwab Charles Investment Management Inc. decreased its holdings in Invacare Co. (NYSE:IVC) by 3.7% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 372,470 shares of the health services provider’s stock after selling 14,200 shares during the period. Schwab Charles Investment Management Inc. owned about 0.95% of Invacare worth $6,481,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also modified their holdings of IVC. WINTON GROUP Ltd bought a new position in Invacare in the fourth quarter worth approximately $5,602,000. Millennium Management LLC raised its stake in Invacare by 118.0% in the fourth quarter. Millennium Management LLC now owns 347,888 shares of the health services provider’s stock worth $5,862,000 after buying an additional 188,331 shares in the last quarter. AXA raised its stake in Invacare by 958.5% in the fourth quarter. AXA now owns 142,900 shares of the health services provider’s stock worth $2,408,000 after buying an additional 129,400 shares in the last quarter. EAM Investors LLC bought a new position in Invacare in the fourth quarter worth approximately $2,153,000. Finally, Monarch Partners Asset Management LLC raised its stake in Invacare by 55.1% in the first quarter. Monarch Partners Asset Management LLC now owns 345,024 shares of the health services provider’s stock worth $6,003,000 after buying an additional 122,639 shares in the last quarter.
Shares of Invacare opened at $19.40 on Friday, Marketbeat Ratings reports. The firm has a market cap of $764.60 million, a PE ratio of -10.05 and a beta of 2.45. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.48 and a current ratio of 2.10. Invacare Co. has a 12-month low of $12.25 and a 12-month high of $20.00.
Invacare (NYSE:IVC) last issued its quarterly earnings results on Monday, May 7th. The health services provider reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.03. The business had revenue of $237.06 million for the quarter, compared to the consensus estimate of $234.08 million. Invacare had a negative return on equity of 13.88% and a negative net margin of 7.60%. The business’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.47) earnings per share. analysts predict that Invacare Co. will post -1.02 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, July 20th. Stockholders of record on Friday, July 6th will be given a dividend of $0.0125 per share. This represents a $0.05 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date of this dividend is Thursday, July 5th. Invacare’s payout ratio is presently -2.59%.
In related news, Director C Martin Harris sold 2,582 shares of the company’s stock in a transaction on Wednesday, May 23rd. The stock was sold at an average price of $16.38, for a total value of $42,293.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Baiju R. Shah sold 4,000 shares of the company’s stock in a transaction on Friday, June 15th. The shares were sold at an average price of $19.65, for a total value of $78,600.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 26,582 shares of company stock worth $512,693. Insiders own 2.10% of the company’s stock.
IVC has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Invacare from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Saturday, May 12th. ValuEngine raised Invacare from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 8th. UBS Group raised Invacare from a “sell” rating to a “neutral” rating in a research report on Wednesday, May 2nd. Finally, KeyCorp reduced their price target on Invacare from $24.00 to $23.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 9th. One analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Invacare presently has a consensus rating of “Buy” and a consensus target price of $21.50.
Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. The company operates through four segments: North America/Home Medical Equipment, Institutional Products Group, Europe, and the Asia/Pacific.
Want to see what other hedge funds are holding IVC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invacare Co. (NYSE:IVC).
Receive News & Ratings for Invacare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invacare and related companies with MarketBeat.com's FREE daily email newsletter.